1-8 of 8
Bob Löwenberg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Double mutant DNMT3A AML: a unique subtype experiencing increased DNA damage and poor prognosis

Emma L. Boertjes, Sanne Massaar, Annelieke Zeilemaker, Jolinda Konijnenburg, Melissa Rijken, François G. Kavelaars, Tim Grob, Jurjen Versluis, Bob Löwenberg, Peter J.M. Valk, Mathijs Arnoud Sanders
Journal: Blood Advances
Blood Adv bloodadvances.2024014698.
https://doi.org/10.1182/bloodadvances.2024014698
Published: 2024
Includes: Supplemental data
Journal Articles

Advantages of a genomic DNA-based NGS assay for detection of mutant NPM1 measurable residual disease in AML

Christian M Vonk, Tim Grob, Melissa Rijken, François G. Kavelaars, Jolinda Konijnenburg, Gert J Ossenkoppele, Markus G. Manz, Yngvar Floisand, Bob Löwenberg, Peter J.M. Valk
Journal: Blood Advances
Blood Adv bloodadvances.2024014490.
https://doi.org/10.1182/bloodadvances.2024014490
Published: 2024
Includes: Supplemental data
Journal Articles

DNA vs cDNA FLT3 -ITD allelic ratio and length measurements in adult acute myeloid leukemia

Clinical Trials & Observations
David G. J. Cucchi, Christian M. Vonk, Melissa Rijken, François G. Kavelaars, Pauline A. Merle, Elvira Verhoef, Bianca Venniker-Punt, Zinia J. Kwidama, Patrycja Gradowska, Bob Löwenberg, Jeroen J. W. M. Janssen, Jacqueline Cloos, Peter J. M. Valk
Journal: Blood Advances
Blood Adv (2021) 5 (21): 4476–4479.
https://doi.org/10.1182/bloodadvances.2021004980
Published: 2021
Includes: Supplemental data
Journal Articles

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Clinical Trials & Observations
Bob Löwenberg, Thomas Pabst, Johan Maertens, Patrycja Gradowska, Bart J. Biemond, Olivier Spertini, Edo Vellenga, Laimonas Griskevicius, Lidwine W. Tick, Mojca Jongen-Lavrencic, Marinus van Marwijk Kooy, Marie-Christiane Vekemans, Walter J. F. M. van der Velden, Berna Beverloo, Lucienne Michaux, Carlos Graux, Dries Deeren, Okke de Weerdt, Joost W. J. van Esser, Mario Bargetzi, Saskia K. Klein, Alain Gadisseur, Peter E. Westerweel, Hendrik Veelken, Michael Gregor, Tobias Silzle, Daniëlle van Lammeren-Venema, Ine Moors, Dimitri A. Breems, Mels Hoogendoorn, Marie-Cecile J. C. Legdeur, Thomas Fischer, Juergen Kuball, Jan Cornelissen, Kimmo Porkka, Gunnar Juliusson, Peter Meyer, Martin Höglund, Bjorn T. Gjertsen, Jeroen J. W. M. Janssen, Gerwin Huls, Jakob Passweg, Jacqueline Cloos, Peter J. M. Valk, Catharina H. M. J. van Elssen, Markus G. Manz, Yngvar Floisand, Gert J. Ossenkoppele
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1110–1121.
https://doi.org/10.1182/bloodadvances.2020003855
Published: 2021
Includes: Supplemental data
Journal Articles

TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML

Clinical Trials & Observations
Jayakumar Vadakekolathu, Catherine Lai, Stephen Reeder, Sarah E. Church, Tressa Hood, Anbarasu Lourdusamy, Michael P. Rettig, Ibrahim Aldoss, Anjali S. Advani, John Godwin, Matthew J. Wieduwilt, Martha Arellano, John Muth, Tung On Yau, Farhad Ravandi, Kendra Sweet, Heidi Altmann, Gemma A. Foulds, Friedrich Stölzel, Jan Moritz Middeke, Marilena Ciciarello, Antonio Curti, Peter J. M. Valk, Bob Löwenberg, Ivana Gojo, Martin Bornhäuser, John F. DiPersio, Jan K. Davidson-Moncada, Sergio Rutella
Journal: Blood Advances
Blood Adv (2020) 4 (20): 5011–5024.
https://doi.org/10.1182/bloodadvances.2020002512
Published: 2020
Includes: Supplemental data
Journal Articles

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Clinical Trials & Observations
Gerwin Huls, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Isabelle van Zeventer, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4267–4277.
https://doi.org/10.1182/bloodadvances.2020002846
Published: 2020
Includes: Supplemental data
Journal Articles

The application of an integrated clinical, cytogenetic, and molecular risk stratification for acute myeloid leukemia patients using a central laboratory in a Brazilian multicentric study

Fernanda Borges da Silva, Lorena Lobo de Figueiredo-Pontes, Maria Isabel Ayrosa Madeira, Luisa Corrêa de Araujo Koury, Ana Silvia Gouvêa de Lima, Priscila Santos Scheucher, Juan Luiz Coelho-Silva, Katia Borgia Barbosa Pagnano, Ronald Pallota, Maria de Lourdes Chauffaille, Marcos Roberto Pedron Oltramari, Rosane Isabel Bittencourt, Marcia Higashi, Rodrigo Miguel Bendlin, Elvira Deolinda Rodrigues Pereira Velloso, Bob Lowenberg, Arnold Ganser, Nancy Berliner, Peter Valk, Eduardo Magalhães Rego, Fabiola Traina
Journal: Blood Advances
Blood Adv (2017) 1 (Suppl): 86–89.
https://doi.org/10.1182/bloodadvances.2017GS102419
Published: 2017
Journal Articles

Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia

Clinical Trials & Observations
Antonio R. Lucena-Araujo, Diego A. Pereira-Martins, Luisa C. Koury, Pedro L. Franca-Neto, Juan L. Coelho-Silva, Virginia M. de Deus Wagatsuma, Raul A. M. Melo, Rosane Bittencourt, Katia Pagnano, Ricardo Pasquini, Carlos S. Chiattone, Evandro M. Fagundes, Maria de Lourdes Chauffaille, Stanley L. Schrier, Martin S. Tallman, Raul C. Ribeiro, David Grimwade, Arnold Ganser, Bob Löwenberg, Francesco Lo-Coco, Miguel A. Sanz, Nancy Berliner, Eduardo M. Rego
Journal: Blood Advances
Blood Adv (2017) 1 (21): 1807–1814.
https://doi.org/10.1182/bloodadvances.2017005926
Published: 2017
Includes: Supplemental data